Abstract. Delta-like-4 (Dll-4) prevents excess angiogenic sprouting and promotes the formation of a well-differentiated vascular network. Therefore, transplantation of Dll-4-overexpressing endothelial progenitor cells (EPCs) was hypothesized to be superior to transplantation of EPCs in the treatment of ischemic heart disease. In the current study, EPCs harvested from C57BL/6 mouse bone marrow were infected in vitro with Dll-4 (EPC ) or Dll-4 knockdown (EPC Dll-4-) with recombinant lentiviral vectors and the control cells were non-transfected or transduced with mock vectors (EPC null ). Eight-week-old C57BL/6 mice underwent ligation of the left anterior descending artery to establish a myocardial infarction (MI) model. The ligated animals were randomly divided into 5 groups, which, following one week, were intravenously injected with EPCs, EPC null , EPC , EPC Dll-4-or medium. Two weeks later, echocardiographic assessment, western blotting, fluorescent microsphere and histological studies were performed. The results demonstrated that the number of mature vessels and blood flow in ischemic myocardium were increased in the EPC Dll-4+ group, but were markedly decreased in the EPC Dll-4-group compared with the control groups. The expression levels of Dll-4, hairy/enhancer of split (Hes)-related protein 1 (Hey-1), phosphorylation of mammalian target of rapamycin (mTOR) and p70S6 kinase (p70S6K) were significantly increased in the EPC Dll-4+ group, while they were markedly decreased in the EPC Dll-4-group. Furthermore, for EPC Dll-4+ -treated animals, an enhanced cardiac function was observed as assessed by echocardiography. Thus, the transplantation of Dll-4-overexpressing EPCs stimulates neovascularization effectively, increases the blood flow to the ischemic zone and improves cardiac function. These effects may be due to the activation of Notch/Hey-1/mTOR/p70S6K signaling pathways, which are initiated by Dll-4.
Introduction
The formation of new blood vessels is an important process required for healing wounds and for restoring blood flow to tissue following injury or insult (1) . A number of stem/progenitor cells, including bone marrow-derived endothelial progenitor cells (EPCs) and mononuclear cell, have been identified for their pro-angiogenic potential to improve perfusion as an experimental or clinical option (2, 3) . As precursors of mature endothelial cells (ECs), EPCs are capable of increasing the neovascularization of ischemic tissue and delaying the initiation and progression of coronary artery disease (4, 5) . Circulating EPCs were found to exhibit similar features of ECs, possess the ability to home to sites of ischemia and contribute to the formation of new blood vessels (6) . Thus, EPCs have been used as seeding cells in tissue engineering and stem cell therapy.
Increasing evidence has demonstrated that the Notch signaling pathway is one of the most important mechanisms involved in the regulation of neovascularization. In mammals, the Notch signaling pathway includes five transmembrane ligands, i.e., Delta-like (Dll)-1, Dll-3, Dll-4, Jagged (Jag)-1 and Jag-2 and four transmembrane receptors, i.e., Notch-1, -2, -3 and -4. The interaction between the Notch receptor and
Transplantation of bone marrow-derived endothelial progenitor cells overexpressing Delta-like-4 enhances functional neovascularization in ischemic myocardium
ligand leads to cleavage of the Notch intracellular domain (NICD) and translocation to the nucleus, thereby activating downstream target genes, including basic helix-loop-helix (bHLH) proteins which include hairy/enhancer of split (Hes) and Hes-related protein (Hey) (7, 8) . The Notch ligand Dll-4 has been identified as a promising new target for angiogenesis in preclinical studies. For example, the balance between sprout and tube formation is established as being important for the generation of a new functional vessel, which is hypothesized to be modulated by Dll-4 from tip ECs to neighboring stalk ECs in order to restrict the emergence of excessive sprout through the repression of vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) transcription and consequently the reduction of responsiveness to VEGF (9, 10) . By contrast, the inhibition of Dll-4-mediated signaling is hypothesized to retard tumor growth, despite an increase of tumor vasculature density since the established vascular network is functionally inefficient (11) (12) (13) , suggesting that Dll-4 attenuates the formation of ineffective vascular branch and promotes the remainder to form functional vessels. Thus, Dll-4-overexpressing EPCs were hypothesized to be superior to untreated EPCs in the formation of productive blood vessels in ischemic myocardium. Isolation, cultivation and identification of EPCs. Two 6-week-old C57BL/6 mice were sacrificed by cervical dislocation. Following removal of the tips of the hind legs and vertebrae, bone marrow was collected by flushing out the content of femurs and tibias with PBS. Mononuclear cells were collected from the bone marrow by density gradient centrifugation using Histopaque 1077 (Sigma-Aldich, St. Louis, MO, USA) according to the manufacturer's instructions. The isolated cells were cultivated in dishes coated with fibronectin (R&D Systems, Minneapolis, MN, USA) and induced by EBM-2 Single Quots (Lonza, Basel, Switzerland) with supplements at 37˚C with 5% CO 2 in humidified air at a density of 5x10 6 cells/cm 2 . Following 3 days in culture, non-adherent cells were removed by washing with PBS, new medium was applied and the cultivation was maintained for 7 days. Immunofluorescence staining and flow cytometry were used to identify EPCs, which was performed as previously described by Liu et al (14) .
Materials and methods

Animal
Recombinant lentiviral vector construction and cell infection. The procedures for recombinant lentiviral vector construction, cell infection and selection of the stable cell line were performed as previously described by Chen and Zhou (15) . In brief, to produce Dll-4 recombinant lentiviral vectors, the plasmids pAJ-Ubi-eGFP-3Flag, psPAX2 (gag/pol element) and pMD2.G (VSVG element) (Auragene Bioscience Inc., Changsha, China) were used according to the manufacturer's instructions. Following lentiviral vector infection, the stable cell line overexpressing Dll-4 was cultured in a 5% CO 2 Western blot analysis. Each sample was lysed in 0.2 ml lysis buffer (Calbiochem, La Jolla, CA, USA). The protein concentrations were determined by the Bradford method (Bio-Rad, Hercules, CA, USA). Total protein (20 µg) was separated on 10% SDS-PAGE gels and transferred to PVDF membranes (Millipore, Billerica, MA, USA) using the semi-dry transfer method. Membranes were blocked for 1 h in Tris-buffered saline containing 0.01% Tween-20 with 10% non-fat dried milk and incubated overnight at 4˚C with the relevant antibodies: Dll-4 and Hey-1 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), mammalian target of rapamycin (mTOR) and phospho-mTOR (Ser2448) antibody (Abcam, Cambridge, UK), p70S6 kinase (p70S6K) and phospho-p70S6K (Thr421/Ser424) antibody (Cell Signaling Technology, Inc., Danvers, MA, USA). Membranes were rinsed and incubated for 1 h with the corresponding peroxidase-conjugated secondary antibodies. Chemiluminescent detection was performed using the ECL kit (Pierce Biotechnology, Inc., Rockford, IL, USA). All bands were analysed using Image J software (version 1.6 NIH).
In vitro angiogenesis assay. Tubulogenesis was induced using an in vitro Angiogenesis Assay kit (#ECM625, Millipore) following the manufacturer's instructions (16) . Briefly, ECMatrix™ solution was thawed on ice overnight, mixed with 10X ECMatrix™ diluents and placed in a 96-well tissue culture plate at 37˚C for 1 h to allow the matrix solution to solidify. EPCs (1x10 4 cells/well) in 50 µl of medium were cultured on the top of the solidified matrix solution. Following 18 h of incubation at 37˚C, the tubule formation was inspected under an inverted light microscope at x200 magnification. Tubule formation was defined as a structure exhibiting a length four times its width. Five random microscopic fields were assessed for each well and the average number and the total length of tubules/200x field was determined and compared with the control cells.
Assessment of cell death induced by H 2 O 2 . The viability of
EPCs was determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) assay. A total of 1x10 4 cells were equally seeded into each well in 96-well microplates. Following incubation with H 2 O 2 for 1 h, the medium was replaced with MTT solution (0.5 mg/ml in PBS). Incubation was continued for 4 h and then the supernatant was gently removed. Dimethyl sulfoxide (DMSO) (Sigma-Aldrich) was added and the absorbance was read at 490 nm on a spectrophotometer (Bio-Rad) and the percentage of cell viability was obtained.
Creation of myocardial infarction (MI) model and cell transplantation.
Eight-week-old C57BL/6 mice (weighing 20±2 g) underwent ligation of the left coronary artery to produce MI. Following anesthetization, the animals were orally intubated with a 1.0-mm OD intubation cannula and connected to a small animal volume-control ventilator (HES-HA MiniVent 845, Harvard Apparatus, Holliston, MA, USA). The left anterior descending artery was ligated 2-3 mm from its origin between the pulmonary artery conus and the left atrium using 8-0 sutures. The ligated animals were monitered by electrocardiograph using the RM6240BD system (Chengdu Instrument Company, Chengdu, China) to determine MI models. One week following coronary ligation, the surviving mice were randomly subdivided into 5 Myocardial blood flow. Measurement of blood flow to the peri-infarcted and infarcted area of mouse hearts was performed as previously described (17).
Capillary density. To identify mature capillary density, the tissue sections (5 µm) of the infarcted zone were stained with anti-VIII factor antibody (Santa Cruz Biotechnology, Inc.). Immunohistochemical staining was performed as previously described (17) .
Statistical analysis. Data are presented as the mean ± SD. A method of ANOVA (analysis of variance) with Scheffe's post-hoc test was used to identify differences among the groups. P<0.05 was considered to indicate a statistically significant difference. (Fig. 1) . Furthermore, a similar alteration was also detected in the EPCs-, EPC null -, EPC Dll-4+ -and EPC Dll-4--treated animals when the peri-infarcted and infarcted heart tissue was extracted for western blot analysis. These observations suggested that the overexpression of Dll-4 results in the increase of its downstream target molecule, Hey-1 and thus, the activation of mTOR signaling pathway.
Results
Efficiency of gene transfection and alteration of relative
signals. qPCR data indicated that Dll-4 gene expression in EPC Dll-4+ was 17-fold higher compared with the expression in EPCs. The Dll-4 mRNA level was ~65.4% lower in EPC Dll-4-compared with EPCs. Western blot analysis showed that the expression of Dll-4, Hey-1, phospho-mTOR and phospho-p70S6K were markedly increased in EPC Dll-4+ and markedly decreased in EPC Dll-4-
Protective effect of Dll-4 on the H 2 O 2 -injured EPCs.
To determine the effect of Dll-4 on the viability of H 2 O 2 -treated EPCs, the cells of each group were exposed to increasing concentrations of H 2 O 2 from 0 to 1,000 µmol/l (data from the pilot study were not shown). The previous study showed that 150 µmol/l H 2 O 2 is the optimal concentration. Dll-4-overexpressing EPCs were more resistant to H 2 O 2 compared with EPCs or EPC null following incubation with the apoptotic stimulus (P<0.01). By contrast, Dll-4-inhibited EPCs were more readily damaged by H 2 O 2 (Fig. 2) .
Capillary-like tube formation. EPCs were seeded on a solidified matrix and incubated with collected medium for 18 h. Quantification of branch points/200x microscopic field demonstrated that the number of tubular structures in the EPC group was higher compared with the EPC and EPC null groups. Tubules in the EPC Dll-4+ group were qualitatively different and more complex compared with those in the control wells. Despite the number of emerging sprouts being greater in the EPC Dll-4-group, they had an irregular and disorganized shape, suggesting that knockdown of the Dll-4 gene impacts on EPCs ability to form functional tubules (Fig. 3) .
Improvement of LV contractile function.
To assess cardiac function, echocardiographic studies were performed 2 weeks post-transplantation. EF and FS were improved in the EPCs, EPC null and EPC Dll-4+ groups when compared with the PBS group (P<0.01 or P<0.001). Furthermore, EF and FS were higher in the EPC Dll-4+ group compared with the EPCs and EPC null groups (P<0.05; Fig. 4 ). However, there was no statistical significance in enhancing cardiac function between EPC Dll-4-and PBS therapy (P>0.05). These results indicate that transplantation of the Dll-4-overexpressing EPCs had an improved therapeutic effect for improving the LV function of MI animals compared with transplantation of untreated EPCs. By contrast, pre-inhibition of Dll-4 in the transplanted cells resulted in a poor effect.
Transplantation of Dll-4-overexpressing EPCs increases to form mature micovessels in ischemic myocardium.
Semiquantitative analysis showed that, 2 weeks following cell transplantation, the number of blood vessels in peri-infarcted and infarcted tissue was significantly increased in the EPC (23.1±4.8) and EPC null (22.6±5.2) groups when compared 
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with the PBS group (13.2±2.4) (P<0.01). The microvessel number was further increased in the EPC Dll-4+ group and an increase in immature vessel proliferation was observed in the peri-infarcted and infarcted area of mouse heart 2 weeks following treatment with EPC Dll-4-, however, mature vessels with a lumen were barely detected (Fig. 5) . This indicated that Dll-4 may contribute to angiogenesis and tubulogenesis in ischemic myocardium.
Treatment of Dll-4-overexpressing EPCs increases the blood flow in ischemic myocardium.
To determine whether new blood vessels translate to increased coronary blood flow to the infarcted myocardium, functional microvessels were identified in the infarcted heart using the fluorescent microsphere method for regional blood flow assessment 2 weeks following transplantation. There was a significant decrease in blood flow to the infarcted and peri-infarcted zone and an increase to ~48% of the normal level was observed when EPCs and EPC null treatment was induced. Notably, transplantation of EPC Dll-4+ further increased the blood flow to ~65.1% that of the normal level. However, no evident improvement was detected when treated with PBS or EPC Dll-4- (Fig. 6 ).
Discussion
In terms of EPCs, abundant evidence supports their involvement in capillary growth and the formation of collateral vessels. These consequent effects have led to improved perfusion and functional recovery in animal models of myocardial and peripheral ischemia (4, 18) . In early clinical trials, the therapeutic administration of EPCs to patients with MI or chronic angina has been associated with positive trends in perfusion (2). However, low survival and the angiogenic potential of treated cells in ischemic myocardium affects the outcome of EPC transplantation for the treatment of ischemic disease. Cell sheet grafts with genetically engineered properties to prolong stem cell survival and promote blood vessel networks integrated with pre-existing coronary may provide a potential approach to repair dead or injured myocardium (19) . The present study suggests that EPCs may be efficiently transfected with lentiviral vectors encoding Dll-4 without any adverse effect on the cell viability and that EPC Dll-4+ exhibit a higher resistance against oxidative stress and the transfected EPCs survive for a longer period of time in the ischemic area.
Vascular network formation is coordinated by VEGF and Dll-4. Dll-4 may act downstream of VEGF as a 'brake' on VEGF-mediated angiogenic sprouting (20) and it may act to prevent overexuberant angiogenic sprouting, promoting the timely formation of a well-differentiated vascular network (21) . Inhibition of Dll-4 induces the proliferation of immature vascular networks and results in poor tissue perfusion (11) (12) (13) . The current in vitro study demonstrated that the number of tubular structures in the EPC Dll-4+ group was higher compared with the EPC and EPC null groups. In in vivo experiments, a significantly greater capacity was observed when productive vessels were formed and further increased blood flow to the infarcted and peri-infarcted zone in the groups receiving EPC , with the exception of the group transplanted with untreated EPCs. Two weeks following cell transplantation, the cardiac function in the Dll-4-overexpressing EPCs group gradually recovered, whereas the PBS and untreated EPCs groups did not exhibit such effects, suggesting that tubulogenesis and enhancement of tissue perfusion played a key role in the improvement of cardiac function in MI animals. EPC Dll-4+ also promotes the formation of mature vessels in the ischemic myocardium and enhances cardiac function. Thus, treated EPCs are hypothesized to be superior to the untreated EPCs. By contrast, specific knockdown of Dll-4 attenuates the ability of EPCs to form mature vascular structures in the in vitro angiogenesis assay. Injection of Dll-4-inhibited EPCs into MI animals, resulted in the formation of a dense capillary network, which appeared irregular and disorganized, thus, unable to supply ischemic myocardium with adequate perfusion. These observations were consistent with a previous study showing that Dll-4 blockade causes functional defects in angiogenesis following ischemia in mouse limp (22) .
With the exception of Notch, the signaling pathways of mTOR are also closely linked to stem cell development and neovascularization. In ECs, mTOR may be necessary for EPC development since inhibition of mTOR pathways with rapamycin may lead to EPC death, which may result from inhibiting growth factor signaling (23) . As an important component of cardiac tissue protection and regeneration, angiogenesis may be regulated by mTOR (24) . Inhibition of mTOR may lead to a sequence of events, including elevated matrix metalloproteinase-1 and the blockade of tissue inhibitor of metalloprotease-3 resulting in impaired angiogenesis (25) . Moreover, loss of mTOR activity may also lead to a blockage of endothelial proliferation and angiogenesis (26) as well as proliferation of EPCs (23) . In the current study, the expression of Notch downstream target molecule, Hey-1 and the phosphorylated status of mTOR and p70S6K (one of mTOR downstream effectors) were significantly increased under a higher expression of Dll-4 in EPCs. EPC Dll-4+ transplantation also led to a similar variation as the mouse ischemic myocardium was extracted for western blot analysis. Notably, an opposite effect was observed in in vitro cultered EPC Dll-4-and the animals treated with EPC null . A previous study by Chan et al observed that Notch signals may positively regulate the activity of the mTOR pathway in T-cell acute lymphoblastic leukemia (27) . Overexpression of Dll-4 was thus hypothesized to increase Hey-1 expression via interaction with the Notch-1 or -4 receptor (28, 29) and in turn activate the mTOR/p70S6K-mediated angiogenesis signaling pathways.
In conclusion, the present study suggests that the intravenous injection of Dll-4-overexpressing EPCs stimulates angiogenesis and tubulogenesis effectively and increases blood flow to the ischemic zone through the activation of Notch/Hey-1/mTOR/p70S6K signaling pathways. The combined strategy of EPCs transplantation with Dll-4 therapy may be proposed as a promising approach for the treatment of ischemic heart disease.
